# A Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D

> **NCT06505928** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai HEP Pharmaceutical Co., Ltd.** · enrollment: 90 (estimated)

## Conditions studied

- Hepatitis D

## Interventions

- **DRUG:** hepalatide

## Key facts

- **NCT ID:** NCT06505928
- **Lead sponsor:** Shanghai HEP Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-11
- **Primary completion:** 2026-05
- **Final completion:** 2026-07
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06505928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06505928, "A Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06505928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*